La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Carisma Therapeutics Croissance future
Future contrôle des critères 0/6
Carisma Therapeutics's revenue and earnings are forecast to decline at 36.4% and 6.9% per annum respectively while EPS is expected to grow by 4% per annum.
Informations clés
-6.9%
Taux de croissance des bénéfices
4.0%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 30.4% |
| Taux de croissance des recettes | -36.4% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 09 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results
May 12
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%
Apr 19We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate
Mar 26Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop
Jan 21The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%
Dec 07Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)
Nov 12Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation
Oct 05We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely
Jun 15Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 10 | -74 | -43 | -41 | 2 |
| 12/31/2025 | 12 | -66 | -39 | -38 | 4 |
| 12/31/2024 | 23 | -56 | -69 | -69 | 3 |
| 6/30/2024 | 21 | -73 | -77 | -76 | N/A |
| 3/31/2024 | 15 | -81 | -79 | -78 | N/A |
| 12/31/2023 | 15 | -87 | -82 | -81 | N/A |
| 9/30/2023 | 14 | -83 | -83 | -82 | N/A |
| 6/30/2023 | 13 | -80 | -73 | -70 | N/A |
| 3/31/2023 | 12 | -75 | -69 | -65 | N/A |
| 12/31/2022 | 10 | -61 | -10 | -5 | N/A |
| 9/30/2022 | 6 | -57 | -2 | 3 | N/A |
| 6/30/2022 | 4 | -49 | -1 | 2 | N/A |
| 3/31/2022 | 1 | -43 | 4 | 7 | N/A |
| 12/31/2021 | N/A | -41 | -39 | -37 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: CARM is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: CARM is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: CARM is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: CARM's revenue is expected to decline over the next 3 years (-36.4% per year).
Croissance élevée des revenus: CARM's revenue is forecast to decline over the next 3 years (-36.4% per year).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if CARM's Return on Equity is forecast to be high in 3 years time